SpringWorks Therapeutics Inc. (NASDAQ:SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks Therapeutics announced that the European Medicine Agency’s Committee for ...

Get the latest news on SpringWorks Therapeutics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SWTX performance ...

Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of ...

SpringWorks Therapeutics expects the EMA to rule on nirogacestat's marketing authorization for desmoid tumors in Q2 2025. Quiver AI Summary. SpringWorks Therapeutics, Inc. announced that it ...

SpringWorks Therapeutics (SWTX) closed the last trading session at $34.71, gaining 15.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

SpringWorks Therapeutics' Gomekli receives FDA approval for NF1-related tumors, showcasing strong efficacy in trials with U.S. launch expected soon.

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $54.36, for a ...

A little over two months after it was announced, Germany-based life sciences firm Merck KGaA said Tuesday that it has completed its $3.9 billion acquisition of Stamford-based SpringWorks Therapeutics ...

Stifel Financial Corp reduced its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 7.7% in the 4th quarter, according to the company in its most recent 13F ...

BofA lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $55 from $58 and keeps a Buy rating on the shares. While political and rate uncertainty continues to be an overhang ...